Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Novel Protein Therapeutics Targeting Ovarian and Breast Cancer
EF 2025-26
Résumé
Breast and ovarian cancers remain major causes of illness and death in Canada, and many of the most aggressive forms are driven by abnormal activation of the MYC oncogene. Although MYC is a highly promising therapeutic target, decades of research have shown that traditional small-molecule drugs cannot effectively block its activity. Recently, protein-based therapeutics have emerged as a novel strategy to inhibit the Myc/Max/E-box network that drives tumour growth. A new class of engineered proteins, known as M2EBi inhibitors, shows improved stability and cellular activity compared to earlier candidates such as Omomyc, but their broader anticancer potential and pharmacological properties have yet to be sufficiently explored.
This project will contribute to the development of next-generation protein therapeutics by evaluating the activity of MEF and MEF-derived inhibitors in breast and ovarian cancer models. I will evaluate their ability to suppress tumour cell growth across multiple cancer cell lines and determine the drug concentrations required for effective inhibition. To understand how these proteins behave in the body, I will also perform foundational pharmacokinetic studies in mice to assess circulation time, distribution, and clearance following drug administration. These experiments will generate essential data needed to guide dosing strategies and future preclinical testing.
By advancing knowledge on the efficacy and pharmacological properties of MEF-based protein drugs, this research will support the development of safer and more effective treatments for MYC-driven cancers. Ultimately, this work has the potential to help establish a new class of targeted therapies for patients with breast and ovarian cancer.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573142
Name
Cheng Jia An
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel Protein Therapeutics Targeting Ovarian and Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Breast Cancer; Cancer Drug; Myc; Pharmacokinetic Studies; Preclinical Studies; Protein Therapeutics; Targeted Efficacy; Triple-Negative Breast Cancer
Abstract
Breast and ovarian cancers remain major causes of illness and death in Canada, and many of the most aggressive forms are driven by abnormal activation of the MYC oncogene. Although MYC is a highly promising therapeutic target, decades of research have shown that traditional small-molecule drugs cannot effectively block its activity. Recently, protein-based therapeutics have emerged as a novel strategy to inhibit the Myc/Max/E-box network that drives tumour growth. A new class of engineered proteins, known as M2EBi inhibitors, shows improved stability and cellular activity compared to earlier candidates such as Omomyc, but their broader anticancer potential and pharmacological properties have yet to be sufficiently explored.
This project will contribute to the development of next-generation protein therapeutics by evaluating the activity of MEF and MEF-derived inhibitors in breast and ovarian cancer models. I will evaluate their ability to suppress tumour cell growth across multiple cancer cell lines and determine the drug concentrations required for effective inhibition. To understand how these proteins behave in the body, I will also perform foundational pharmacokinetic studies in mice to assess circulation time, distribution, and clearance following drug administration. These experiments will generate essential data needed to guide dosing strategies and future preclinical testing.
By advancing knowledge on the efficacy and pharmacological properties of MEF-based protein drugs, this research will support the development of safer and more effective treatments for MYC-driven cancers. Ultimately, this work has the potential to help establish a new class of targeted therapies for patients with breast and ovarian cancer.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cheng, Jia An
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~